A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
文献类型：期刊论文
| 作者 | Zhang, Hui1; Hu, Ke1; Lu, Yumeng1; Xu, Zhijian2 ; Chen, Gege1; Yu, Dandan2; Gao, Xuejie1; Feng, Qilin1; Jia, Xinyan1; Xu, Li1
|
| 刊名 | INTERNATIONAL IMMUNOPHARMACOLOGY
 |
| 出版日期 | 2024-01-25 |
| 卷号 | 127页码:14 |
| ISSN号 | 1567-5769 |
| 关键词 | Multiple myeloma M1 macrophages Th1 cells Immunomodulatory |
| DOI | 10.1016/j.intimp.2023.111446 |
| 通讯作者 | Li, Bo(boli@simm.ac.cn) ; Zhu, Weiliang(wlzhu@simm.ac.cn) ; Shi, Jumei(shijumei@tongji.edu.cn) |
| 英文摘要 | Multiple myeloma (MM) is an incurable and recurrent malignancy characterized by abnormal plasma cell proliferation. There is an urgent need to develop effective drugs in MM. DCZ0825 is a small molecule compound derived from pterostilbene with direct anti-myeloma activity and indirect immune-killing effects though reversal of the immunosuppression. DCZ0825 inhibits the activity and proliferation of MM cells causing no significant toxicity to normal cells. Using flow cytometry, this study found that DCZ0825 induced caspase-dependent apoptosis in MM cells and arrested the cell cycle in the G2/M phase by down-regulating CyclinB1, CDK1 and CDC25. Moreover, DCZ0825 up-regulated IRF3 and IRF7 to increase IFN-gamma, promoting M2 macrophages to transform into M1 macrophages, releasing the immunosuppression of CD4T cells and stimulated M1 macrophages and Th1 cells to secrete more INF-gamma to form immune killing effect on MM cells. Treatment with DCZ0825 resulted in an increased proportion of positive regulatory cells such as CD4T, memory T cells, CD8T, and NK cells, with downregulation of the proportion of negative regulatory cells such as Treg cells and MDSCs. In conclusion, DCZ0825 is a novel compound with both antitumor and immunomodulatory activity. |
| WOS关键词 | REGULATORY T-CELLS ; MULTIPLE-MYELOMA ; APOPTOSIS ; CANCER ; DIAGNOSIS ; IMMUNITY ; TARGETS ; DEATH |
| 资助项目 | National Natural Science Foundation of China[81971529] ; National Natural Science Foundation of China[82000220] ; National Natural Science Foundation of China[82170200] ; National Natural Science Foundation of China[82070224] ; National Natural Science Foundation of China[22077131] ; Chinese Pharmaceutical Association-Yiling Biopharmaceutical Innovation Project[CPAYLJ201908] ; State Key Laboratory of Natural and Biomimetic Drugs[K202108] |
| WOS研究方向 | Immunology ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | ELSEVIER |
| WOS记录号 | WOS:001164868900001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309563]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Li, Bo; Zhu, Weiliang; Shi, Jumei |
| 作者单位 | 1.Tongji Univ, Shanghai East Hosp, Dept Hematol, Sch Med, Shanghai 200120, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China 3.Tongji Univ, Shanghai Peoples Hosp 10, Dept Hematol, Sch Med, Shanghai 200072, Peoples R China 4.Tongji Univ, Shanghai East Hosp, Shanghai Inst Mat Med, Drug Discovery & Design Ctr,Sch Med, 150 Jimo Rd, Shanghai 200120, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Hui,Hu, Ke,Lu, Yumeng,et al. A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory[J]. INTERNATIONAL IMMUNOPHARMACOLOGY,2024,127:14. |
| APA | Zhang, Hui.,Hu, Ke.,Lu, Yumeng.,Xu, Zhijian.,Chen, Gege.,...&Shi, Jumei.(2024).A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory.INTERNATIONAL IMMUNOPHARMACOLOGY,127,14. |
| MLA | Zhang, Hui,et al."A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory".INTERNATIONAL IMMUNOPHARMACOLOGY 127(2024):14. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。